We are live on ! Find out more
SGH

Sivik Global Healthcare Portfolio holdings

AUM $132M
1-Year Est. Return 24.1%
This Fund
S&P 500
This Quarter Est. Return
-0.67%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$198M
AUM Growth
-$215M
Cap. Flow
-$211M
Cap. Flow %
-106.36%
Top 10 Hldgs %
35.51%
Holding
63
New
3
Increased
15
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
ALC icon
Alcon
ALC
+$6M
2
GRFS
Grifois
GRFS
+$4.18M
3
ZTS icon
Zoetis
ZTS
+$3.62M
4
CI icon
Cigna
CI
+$3.25M
5
HCA icon
HCA Healthcare
HCA
+$2.58M

Sector Composition

Rank Sector Weight
1 Healthcare 95.79%
2 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BSX icon
1
Boston Scientific
BSX
$69.6B
$8.14M 4.11%
200,000
UHS icon
2
Universal Health Services
UHS
$10.3B
$7.44M 3.75%
50,000
+10,000
+25% +$1.44M
HUM icon
3
Humana
HUM
$43.5B
$7.41M 3.74%
29,000
-3,500
-11% -$981K
HCA icon
4
HCA Healthcare
HCA
$88.4B
$7.22M 3.65%
60,000
+20,000
+50% +$2.58M
MRK icon
5
Merck
MRK
$323B
$7.16M 3.61%
89,080
+15,720
+21% +$1.26M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$124B
$6.78M 3.42%
40,000
+10,000
+33% +$1.77M
ABT icon
7
Abbott
ABT
$181B
$6.69M 3.38%
80,000
BAX icon
8
Baxter International
BAX
$14.2B
$6.56M 3.31%
75,000
-10,000
-12% -$854K
DHR icon
9
Danaher
DHR
$140B
$6.5M 3.28%
50,760
-5,640
-10% -$706K
SNY icon
10
Sanofi
SNY
$103B
$6.49M 3.27%
140,000
+40,000
+40% +$1.73M
LLY icon
11
Eli Lilly
LLY
$1.04T
$6.15M 3.1%
55,000
BIO icon
12
Bio-Rad Laboratories Class A
BIO
$9.2B
$5.99M 3.02%
18,000
+500
+3% +$163K
GRFS
13
Grifois
GRFS
$5.38B
$5.91M 2.98%
295,000
+194,980
+195% +$4.18M
ALC icon
14
Alcon
ALC
$34.5B
$5.83M 2.94%
+100,000
New +$6M
REGN icon
15
Regeneron Pharmaceuticals
REGN
$79.8B
$5.55M 2.8%
20,000
EW icon
16
Edwards Lifesciences
EW
$51.9B
$5.5M 2.77%
75,000
-18,000
-19% -$1.26M
UNH icon
17
UnitedHealth
UNH
$372B
$5.43M 2.74%
25,000
-5,000
-17% -$1.21M
SYK icon
18
Stryker
SYK
$130B
$5.41M 2.73%
25,000
+10,000
+67% +$2.14M
DGX icon
19
Quest Diagnostics
DGX
$26B
$5.35M 2.7%
50,000
+20,000
+67% +$2.05M
WCG
20
DELISTED
Wellcare Health Plans, Inc.
WCG
$5.18M 2.62%
20,000
BDX icon
21
Becton Dickinson
BDX
$47B
$5.06M 2.55%
20,500
-12,813
-38% -$3.16M
LH icon
22
Labcorp
LH
$25.4B
$5.04M 2.54%
34,920
-5,820
-14% -$849K
CELG
23
DELISTED
Celgene Corp
CELG
$4.96M 2.51%
50,000
-10,000
-17% -$950K
IQV icon
24
IQVIA
IQV
$38.7B
$4.48M 2.26%
30,000
+15,000
+100% +$2.33M
TMO icon
25
Thermo Fisher Scientific
TMO
$213B
$4.37M 2.2%
15,000

Similar funds

Sivik Global Healthcare's Q3 2019 Portfolio in Review

As of Q3 2019, Sivik Global Healthcare held 63 positions worth $198M, down 52% from $414M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sivik Global Healthcare withdrew a net $211M in Q3 2019, closing 19 positions and reducing 20 holdings. Its most notable exit was Pfizer, an estimated $6.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 58% a quarter earlier, followed by Energy.

Against the trend, Sivik Global Healthcare opened a new position in Alcon worth $5.83M.

  • Sivik Global Healthcare's largest Q3 2019 buy was Alcon: 100,000 shares worth $5.83M.
  • Sivik Global Healthcare added most to Grifois in Q3 2019, an estimated $4.18M increase.
  • Sivik Global Healthcare's biggest Q3 2019 reduction was Becton Dickinson, cutting an estimated $3.16M.
  • Sivik Global Healthcare fully exited Pfizer in Q3 2019, selling an estimated $6.5M.
  • Sivik Global Healthcare's ten largest holdings make up 36% of its $198M portfolio in Q3 2019.
  • Sivik Global Healthcare opened 3 new positions and closed 19 in Q3 2019.
  • Sivik Global Healthcare's portfolio value fell 52% quarter-over-quarter to $198M.

Based on Sivik Global Healthcare's 13F filing for Q3 2019, filed 12 Nov 2019.